Rivaroxaban has been found to be more efficient than asprin in reducing recurrent venous thromboembolism events, according to recently released results from the EINSTEIN CHOICE trial, published in the New England Journal of Medicine and presented at the American College of Cardiology’s 66th Annual Scientific Session & Expo. – See More
If you’ve been diagnosed with PE or DVT, you might be left with many unanswered questions, feeling very confused about why this happened to you. In many patients, the ultimate cause of thrombosis is still largely unknown. However, there are factors that can make you more likely to develop a blood clot. – See More
Sign up to recieve our quarterly print newsletter, The Beat.
Dedicated to providing patients and healthcare providers with the information they need to combat thrombosis, The Beat features a wide range of articles, including updates on ground breaking research being done in the field of thrombosis, patient profiles, heart healthy tips from medical experts, healthy recipes specifically chosen for patients with thrombosis, and updates on the ever-growing programs that NATF puts on throughout the year. Readers get a first-hand look at NATF’s upcoming events and initiatives.
In addition, The Beat also features an “Ask the Expert” section where thrombosis specialists address questions from patients, covering topics that range aneurysms of the aorta to blood clot formation.
DVT, PE, and Post-thrombotic Syndrome
If you sit and just talk on your cell
Or lie in bed ‘cause you’re not feeling well
Your blood may stagnate
Your thrombosis may then hurt like hell.
Or maybe you won’t feel a thing
Not an ache or a pain or a sting
A big silent clot
That may or may not
Loosen up and break off and take wing...(continued)
The PEPPER trial is investigating which blood thinner is best for patients to use after total hip and knee replacement surgery to prevent blood clots. Researchers are currently looking to enroll 25,000 patients across 25 sites in North America. To learn more and to find out if the trial is recruiting near you, visit the PEPPER trial's website. If you would like to participate, please contact the program manager, Carol Lambourne at 843-792-2913 or email@example.com.
April 20-22, 2017
Los Angeles, CA
Early Bird Registration Ends December 15
3-Day symposium will bring together medical professionals in fields ranging from cardiology and hematology to pharmacy and family medicine for discussions on current research and evidence-based practices in the field of antithrombotic therapy. In addition to presentations by leading experts, the conference will feature small, topic-specific master classes, a "meet the expert" breakfast, poster sessions and industry exhibits.
For more information and to register, visit acforum2017.org
For this program, entitled 'Pushing the Envelope in Cardiovascular Disease Prevention: Novel Risk Factors, New Therapies, and One Brave Idea', four experts in the field of Thrombosis Medicine will share updates including innovative ways to prevent and treat diabetes and metabolic syndrome, whether a simple blood test can predict your risk of developing cardiovascular disease, new medications to lower cholesterol, and a glimpse into the largest ever research project to cure heart disease.
Offering patients the chance to ask questions, share common concerns, support one another, and learn up-to-date and accurate information about VTE. In upcoming months, we will have alternating physicians serving as moderators for group, each with their own perspective.
Upcoming Support Group Dates: April 24th at 7:00 pm with John Fanikos RPh, MBA, the Director of Pharmacy at Brigham and Women's Hospital.
SIGN UP NOW to receive information on how to join a support group.
What different outcomes do men and women face when it comes to VTE? – See More
If you’ve had PE or DVT previously, it can be hard to differentiate between the pain brought on from a previous episode and possible symptoms of a new issue. Here's a closer look at when you should seek medical care and what to expect. – See More
The North American Thrombosis Forum is doubling down on its commitment to supporting patients and caregivers. NATF is proud to announce that it will be expanding its successful support group program beyond Boston, spreading new in-person support groups across North America. – See More
What are non-vitamin K antagonist oral anticoagulants (NOACs) and how are they managed differently from Warfarin? – See More
For many years, Warfarin was the only oral anticoagulant commonly used to treat blood clots. In the past five years, the FDA has approved four new oral anticoagulants for the treatment of DVT, PE, and SPAF. Find out the differences between the five FDA-approved oral anticoagulants. View the Chart.